Volume 70, Issue 6, Pages (September 2006)

Slides:



Advertisements
Similar presentations
M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky 
Advertisements

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma  Ya-Wei Qiang, Bart.
Volume 67, Issue 3, Pages (March 2005)
Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells  Y. Huang, N.A. Noble, J. Zhang, C. Xu, W.A.
Volume 70, Issue 8, Pages (October 2006)
Volume 82, Issue 1, Pages (July 2012)
Canonical Wnt/β-catenin signaling mediates transforming growth factor-β1-driven podocyte injury and proteinuria  Dan Wang, Chunsun Dai, Yingjian Li, Youhua.
Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells  W. Qi, X. Chen, S. Twigg, T.S. Polhill,
Volume 62, Issue 3, Pages (September 2002)
IL-2–mediated apoptosis of kidney tubular epithelial cells is regulated by the caspase-8 inhibitor c-FLIP  Caigan Du, Qiunong Guan, Ziqin Yin, Robert.
Volume 60, Issue 2, Pages (August 2001)
Volume 88, Issue 4, Pages (October 2015)
Volume 69, Issue 4, Pages (February 2006)
Volume 80, Issue 7, Pages (October 2011)
Volume 67, Issue 3, Pages (March 2005)
Volume 69, Issue 4, Pages (February 2006)
Human renal epithelial cells produce the long pentraxin PTX3
Volume 115, Issue 6, Pages (December 1998)
Volume 69, Issue 8, Pages (April 2006)
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone.
Volume 85, Issue 5, Pages (May 2014)
Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells  Y. Huang, N.A. Noble, J. Zhang, C. Xu, W.A.
Volume 62, Issue 4, Pages (October 2002)
M.H.A. Baccora, P. Cortes, C. Hassett, D.W. Taube, J. Yee 
Volume 67, Issue 4, Pages (April 2005)
Neal X. Chen, Kalisha D. O'Neill, Danxia Duan, Sharon M. Moe 
C.S. Ritter, H.J. Armbrecht, E. Slatopolsky, A.J. Brown 
Volume 71, Issue 3, Pages (February 2007)
Volume 66, Issue 4, Pages (October 2004)
Volume 59, Issue 5, Pages (May 2001)
Volume 62, Issue 3, Pages (September 2002)
Effect of advanced glycation end-products on gene expression and synthesis of TNF-α and endothelial nitric oxide synthase by endothelial cells  Gloria.
Volume 68, Issue 1, Pages (July 2005)
Evidence for low-density lipoprotein–induced expression of connective tissue growth factor in mesangial cells  Mimi Sohn, Yan Tan, Richard L. Klein, Ayad.
Expression of inter-α-trypsin inhibitor and tumor necrosis factor-stimulated gene 6 in renal proximal tubular epithelial cells  Ulf Janssen, Gareth Thomas,
Volume 60, Issue 4, Pages (October 2001)
Hsueh Yang, Gabrielle Curinga, Cecilia M. Giachelli 
Volume 69, Issue 6, Pages (March 2006)
PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice
Enhancing and maintaining chondrogenesis of synovial fibroblasts by cartilage extracellular matrix protein matrilins  M. Pei, M.D., Ph.D., J. Luo, M.D.,
Volume 70, Issue 9, Pages (November 2006)
1,25-dihydroxyvitamin D3 inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression  Yingjian Li, Bradley C.
Regulation of renal proximal tubular epithelial cell hyaluronan generation: Implications for diabetic nephropathy  Stuart Jones, Suzanne Jones, Aled Owain.
Volume 62, Issue 1, Pages (July 2002)
Volume 60, Issue 3, Pages (September 2001)
Chemical and hormonal determinants of vascular calcification in vitro
Volume 56, Issue 1, Pages (July 1999)
Vitamin D activates type A natriuretic peptide receptor gene transcription in inner medullary collecting duct cells  S. Chen, K. Olsen, C. Grigsby, D.G.
Volume 70, Issue 10, Pages (November 2006)
P. Harding, L. Balasubramanian, J. Swegan, A. Stevens, W.F. Glass 
Characterization of Keratinocyte Differentiation Induced by Ascorbic Acid: Protein Kinase C Involvement and Vitamin C Homeostasis1  Isabella Savini, Antonello.
M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky 
Volume 65, Issue 3, Pages (March 2004)
Volume 67, Issue 6, Pages (June 2005)
Volume 67, Issue 4, Pages (April 2005)
Volume 70, Issue 5, Pages (September 2006)
Volume 67, Issue 6, Pages (June 2005)
Effect of asymmetric dimethylarginine on osteoblastic differentiation
Lipoxin A4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells  S.-H. Wu, X.-H. Wu, C. Lu, L. Dong, G.-P.
Volume 67, Issue 6, Pages (June 2005)
Volume 56, Issue 1, Pages (July 1999)
Volume 64, Issue 1, Pages (July 2003)
Volume 55, Issue 2, Pages (February 1999)
Volume 70, Issue 8, Pages (October 2006)
John M. Lamar, Vandana Iyer, C. Michael DiPersio 
Volume 77, Issue 5, Pages (March 2010)
IL-1β induces VEGF, independently of PGE2 induction, mainly through the PI3-K/mTOR pathway in renal mesangial cells  D. Solà-Villà, M. Camacho, R. Solà,
Volume 71, Issue 8, Pages (April 2007)
The Activity of Caspase-1 Is Increased in Lesional Psoriatic Epidermis
Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in.
Presentation transcript:

Volume 70, Issue 6, Pages 1046-1053 (September 2006) The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells  N.X. Chen, D. Duan, K.D. O'Neill, G.O. Wolisi, J.J. Koczman, R. LaClair, S.M. Moe  Kidney International  Volume 70, Issue 6, Pages 1046-1053 (September 2006) DOI: 10.1038/sj.ki.5001663 Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 1 ALP activity and osteocalcin expression in BVSMCs treated with normal or uremic serum after transient transfection with the dominant-negative RUNX2 (ΔRUNX2) construct. (a) ALP activity and (b) osteocalcin expression in BVSMCs treated with normal or uremic serum after transient transfection with the dominant-negative RUNX2 (ΔRUNX2) construct. BVSMCs were transfected with a dominant-negative RUNX2 or with pEF-BOS empty vector as a negative control. After transfection, cells were incubated in the presence of 10% normal serum or uremic serum for 72h. Cellular proteins were solubilized and supernatants were assayed for ALP activity normalized to (a) cellular protein content or (b) osteocalcin expression by Western blotting. Data are shown as mean±s.d. from three experiments. Non-T: non-transfected; T: transfected; EV: empty vector. *P<0.05, uremic vs normal; #P<0.05, uremic/NT vs uremic/T. Kidney International 2006 70, 1046-1053DOI: (10.1038/sj.ki.5001663) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 2 RUNX2 expression and ALP activity in BVSMCs treated with normal or uremic serum in the presence or absence of PKA inhibitor (KT5720). (a) RUNX2 expression and (b) ALP activity in BVSMCs treated with normal or uremic serum in the presence or absence of PKA inhibitor (KT5720). Cells were incubated in the presence of 10% normal serum or uremic serum with or without 10μmol/l KT5720 (a specific inhibitor of PKA) for 48h (RUNX2) or 72h (ALP activity). (a) Total RNA was isolated and RUNX2 RT-PCR was performed using β-actin as an internal control, and the ratio determined. (b) Cellular proteins were solubilized and supernatants were assayed for ALP activity normalized to cellular protein content. Data are shown as mean±s.d. from three to four experiments. *P<0.05, uremic vs normal; #P<0.05, uremic vs uremic+KT5720. Kidney International 2006 70, 1046-1053DOI: (10.1038/sj.ki.5001663) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 3 RUNX2 expression and ALP activity in BVSMCs treated with normal or uremic serum in the presence or absence of PKC inhibitor (GF10923X). (a) RUNX2 expression and (b) ALP activity in BVSMCs treated with normal or uremic serum in the presence or absence of PKC inhibitor (GF10923X). Cells were incubated in the presence of 10% normal serum or uremic serum with or without 10μmol/l GF10923X (a specific inhibitor of PKC) for 48h (RUNX2 expression) or 72h (ALP activity). (a) Total RNA was isolated and RUNX2 RT-PCR was performed using β-actin as an internal control, and the ratio determined. (b) Cellular proteins were solubilized and supernatants were assayed for ALP activity normalized to cellular protein content. Data are shown as mean±s.d. from three to four experiments. *P<0.05, uremic vs normal. Kidney International 2006 70, 1046-1053DOI: (10.1038/sj.ki.5001663) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 4 RT-PCR analysis of the expression of RUNX2 in BVSMCs in the presence or absence of an inhibitor of BMP. BVSMCs were incubated with normal or uremic serum in the presence or absence of 1μg/ml of noggin, a specific inhibitor of BMP binding to its receptor, for 48h. Total RNA was isolated and the expression of RUNX2 was determined by RT-PCR. β-Actin was used as an internal control and the ratio determined. Data are shown as mean±s.d. from three experiments. *P<0.05, uremic vs normal. Kidney International 2006 70, 1046-1053DOI: (10.1038/sj.ki.5001663) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 5 BMP-2 serum concentrations in individual dialysis patients over a 3-month period. Serum was collected from 10 individual dialysis patients at monthly intervals over 3 months (days 1, 30, 60, and 90) and BMP-2 concentrations were determined by enzyme-linked immunosorbent assay. Each symbol/line represents a different patient. The results show a large variability in BMP-2 levels over time. Kidney International 2006 70, 1046-1053DOI: (10.1038/sj.ki.5001663) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 6 BMP-2 secretion from BVSMCs treated with normal or uremic serum during calcification. BVSMCs were incubated with calcification media (10mmol/l β-glycerophosphate, 10−7mol/l insulin, and 50μg/ml ascorbic acid) in the presence of either 15% normal or uremic serum for up to 14 days. Conditioned media from BVSMC cultures were collected and BMP-2 measured by the enzyme-linked immunosorbent assay kit. The preincubation levels of BMP-2 were subtracted from post-incubation levels. Data are shown as mean±s.d. from three experiments. *P<0.05, uremic vs normal at each time point; P<0.05 for progression of BMP-2 secretion over time. Kidney International 2006 70, 1046-1053DOI: (10.1038/sj.ki.5001663) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 7 The effect of BMP-2 in calcification of BVSMCs. BVSMCs were treated with or without recombinant human BMP-2 (500ng/ml) in the presence of calcification media (10mmol/l β-glycerophosphate, 10−7mol/l insulin, and 50μg/ml ascorbic acid) with 15% fetal bovine serum for 7 and 14 days, and calcium deposition measured. Data are shown as mean±s.d. from three experiments. *P<0.05, BMP-2 treatment vs control, same day; #P<0.05, day 14 vs day 7, same treatment. Kidney International 2006 70, 1046-1053DOI: (10.1038/sj.ki.5001663) Copyright © 2006 International Society of Nephrology Terms and Conditions